MediciNova, Inc.
Stock Price Chart
2026/11/13 19:59 UpdatedPrice Trend
2026/11/13 19:59 UpdatedPrice & Trading Details
2026/11/13 19:59 UpdatedPRICE
TRADING
Analyst Recommendations 3 analysts
Updated 2026/11/01Earnings Calendar
Updated 2026/11/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/08/13 | ¥-10.43 | ¥-7.97 | +23.6% |
| 2026/05/14 | ¥-10.37 | ¥-7.91 | +23.8% |
| 2026/02/20 | ¥-14.53 | ¥-7.75 | +46.7% |
| 2025/11/12 | ¥-18.50 | ¥-9.29 | +49.8% |
Shareholder Composition
Updated 2026/11/01Top Mutual Funds / ETFs
Updated 2026/11/01Major Holders
Updated 2026/11/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund
|
609.1K | -0.33% | |
|
Fidelity Concord Street Trust-Fidelity Extended Market Index Fund
|
249.9K | -0.53% | |
|
iShares Trust-iShares Micro-Cap ETF
|
151.7K | -3.97% | |
|
Fidelity Concord Street Trust-Fidelity Total Market Index Fund
|
87.6K | 0.00% | |
|
SCHWAB CAPITAL TRUST-Schwab Total Stock Market Index Fund
|
71.5K | 0.00% | |
|
Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund
|
68.4K | 0.00% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Essex Woodlands Management Inc.
|
1.1M | 0.00% | |
|
Blackrock Inc.
|
752.1K | +6.54% | |
|
Citigroup Inc.
|
635.7K | 0.00% | |
|
Vanguard Capital Management LLC
|
609.1K | -0.33% | |
|
Geode Capital Management, LLC
|
539.3K | -0.83% | |
|
Vanguard Fiduciary Trust Co
|
282.6K | +0.71% |
Financial Performance
2026/11/08 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2025 | |
|---|---|---|
| Income Statement | ||
| Revenue | ¥1M | ¥0M |
| Gross Profit | - | ¥0M |
| Operating Income | -¥10M | -¥13M |
| Pretax Income | -¥10M | -¥13M |
| Net Income | -¥9M | -¥12M |
| EPS | -¥0.17 | -¥0.24 |
| Operating Margin | -990.03% | -3,242.47% |
| Balance Sheet | ||
| Total Assets | ¥66M | ¥46M |
| Total Equity | ¥62M | ¥42M |
| Total Liabilities | ¥4M | ¥4M |
| Cash | ¥51M | ¥31M |
| Interest-bearing Debt | ¥0M | ¥0M |
| Equity Ratio | 94.13% | 91.19% |
| D/E Ratio | 0.00 | 0.00 |
| Cash Flow | ||
| Operating CF | -¥7M | -¥10M |
| Investing CF | ¥40M | -¥0M |
| Financing CF | - | ¥0M |
| Free CF | -¥7M | -¥10M |
| Efficiency | ||
| ROE | -13.74% | -28.85% |
| ROA | -12.93% | -26.31% |
Latest IR Information
-
Supplementary Earnings Presentation
Consolidated results for Q3 of the fiscal year ending December 2026 remained in deficit. Revenue was 123,507 thousand yen, operating loss was -1,329,199 thousand yen, and net loss was -1,219,888 thousand yen. R&D expenses were 557,766 thousand yen and general...
Read more -
Quarterly Financial Summary for the Third Quarter of Fiscal Year Ending December 2026 [U.S. GAAP] (Consolidated)
For the third quarter of fiscal year ending December 2026, consolidated revenue totaled 783,978 thousand USD (YoY comparison unknown). Operating loss was -8,437,219 thousand USD, and net loss attributable to owners of parent for the quarter was -7,743,359 thousand USD....
Read more -
Notice of Establishment of Shelf for New Share Issuance Under U.S. Registration Procedures and Issuance of New Shares
Established a new share issuance shelf of 50 million USD as a U.S. ATM Offering. Sales agent: Lucid Capital Markets; fee: 3.0% of gross proceeds. Offerings targeted to the U.S. market, from 2025-12-29 until the shelf limit is reached. Proceeds...
Read more -
Notice of Change in Major Shareholders
Announcement of a change in major shareholders. Following the filing of Schedule 13D/A, 3D Investment Partners Private Limited's ownership fell below 10%, and it no longer qualifies as a major shareholder. There is no direct impact expected on future performance....
Read more -
Notice Regarding Top-line Results of the Phase 2 Clinical Trial (MN-001-NATG-202) of MN-001 (Taipercast) for Hypertriglyceridemia and Fatty Liver Disease Associated with Type 2 Diabetes
Top-line Phase 2 results of MN-001 (Taipercast) showed a significant reduction in TG, significant increases in HDL-C and HDL-P, and trends toward improvement in liver fat content and body weight. Safety was favorable. Further large-scale trials to evaluate efficacy will...
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥-
Rating Score: 1.25 (Based on 3 analysts)
※1=Strong Buy, 5=Strong Sell
MediciNova Inc reports results for the quarter ended September 30 - Earnings Summary - TradingView ↗
MediciNova: Q3 Earnings Snapshot - 10TV ↗
Company Information
About
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
